
Opinion|Videos|June 2, 2025
Real-World Experience: The Efficacy and Tolerability of Oral Elacestrant for Patients with ESR1 Mutations
Author(s)Virginia Kaklamani, MD, DSc, Megan Kruse, MD
Panelists discuss how real-world studies have shown improved outcomes with elacestrant compared with the original EMERALD trial data, demonstrating that proper patient selection leads to better treatment responses.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Clinical Brief: Real-World Evidence Supporting Elacestrant Use
Main Discussion Topics:
- Real-world outcomes exceeding clinical trial results (unusual finding)
- GUARDIAN database analysis: 6.4 months median time to treatment failure
- Komoda database: 6.8 months progression-free survival (9.4 months if fulvestrant-naive)
- Expert clinical experience aligning with real-world data
- Importance of appropriate patient selection for optimal outcomes
Key Points for Physicians:
- Real-world PFS (6.4-6.8 months) exceeds EMERALD trial results (3.8 months)
- Fulvestrant-naive patients show particularly strong outcomes (9.4 months)
- Early adopters report better results with refined patient selection
- Confirms benefit of using elacestrant in second-line for appropriate patients
- Real-world data validates subgroup findings from EMERALD
The real-world evidence conclusively demonstrates that proper patient selection based on EMERALD subgroup analyses results in significantly improved clinical outcomes compared with the overall trial population.
Advertisement
Related to this article

During a live event, Ruta Rao, MD, and participants discussed how toxicity history, rather than head-to-head trial data, drives the choice among 3 antibody-drug conjugates once the first one fails or becomes intolerable.

The B7-H3–targeted antibody-drug conjugate tambotatug pelitecan significantly reduced the risk of death in patients with small cell lung cancer.

The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.

KEYNOTE-D46 shows sacituzumab govitecan plus pembrolizumab misses PFS/OS targets in PD-L1–high metastatic NSCLC, despite higher responses and toxicity.

New RASolute trials test daraxonrasib for metastatic and resected pancreatic cancer, comparing combos and follow-up use to improve outcomes.

The phase 3 DESTINY-Lung04 trial showed first-line trastuzumab deruxtecan extended PFS in patients with HER2-mutant NSCLC.

Updated PRESERVE-003 data showed gotistobart nearly doubled median OS vs docetaxel in previously treated squamous NSCLC.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Daraxonrasib Combo Receives FDA Breakthrough Status in First-Line PDAC
2
Sacituzumab Govitecan Combo Misses PFS End Point in PD-L1–High NSCLC
3
After the First ADC Fails, HR-Positive Breast Cancer Sequencing Runs on Judgment, Not Trial Data
4
Tam-Peli Extends Survival in Relapsed Small Cell Lung Cancer
5
